<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alembic Pharmaceuticals Limited — News on 6ix</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited</link>
<description>Latest news and press releases for Alembic Pharmaceuticals Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sat, 25 Apr 2026 15:58:30 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alembic-pharmaceuticals-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836493178dffbe2df1526c5.webp</url>
<title>Alembic Pharmaceuticals Limited</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited</link>
</image>
<item>
<title>Press Release Apr 25 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-25-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-25-2026-1</guid>
<pubDate>Sat, 25 Apr 2026 15:58:30 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Fingolimod Capsules 0.5 mg.".</description>
</item>
<item>
<title>Press Release Apr 16 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-16-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-16-2026-3</guid>
<pubDate>Thu, 16 Apr 2026 15:17:08 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 16, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Methotrexate Injection USP".</description>
</item>
<item>
<title>Press Release Apr 07 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-07-2026-15</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-apr-07-2026-15</guid>
<pubDate>Tue, 07 Apr 2026 16:24:29 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg.".</description>
</item>
<item>
<title>Press Release Mar 27 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-mar-27-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-mar-27-2026-8</guid>
<pubDate>Fri, 27 Mar 2026 19:19:30 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg.".</description>
</item>
<item>
<title>Press Release Mar 06 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-mar-06-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-mar-06-2026-1</guid>
<pubDate>Fri, 06 Mar 2026 14:06:00 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 06, 2026, titled "Alembic Pharmaceuticals Reports First Prescription Sale of Pivya® (pivmecillinam) Following US Commercial Launch through Alembic Therapeutics LLC".</description>
</item>
<item>
<title>Press Release Feb 26 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-26-2026-11</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-26-2026-11</guid>
<pubDate>Thu, 26 Feb 2026 15:44:12 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg".</description>
</item>
<item>
<title>Press Release Feb 24 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-24-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-24-2026-6</guid>
<pubDate>Tue, 24 Feb 2026 19:29:15 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%".</description>
</item>
<item>
<title>Press Release Feb 06 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-06-2026-13</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-06-2026-13</guid>
<pubDate>Fri, 06 Feb 2026 16:31:51 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Carbidopa, Levodopa and Entacapone Tablets.".</description>
</item>
<item>
<title>Press Release Feb 05 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-05-2026-25</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-feb-05-2026-25</guid>
<pubDate>Thu, 05 Feb 2026 19:08:06 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 05, 2026, titled "Press Release on the Unaudited Financial Results for the quarter and nine months ended 31st December, 2025".</description>
</item>
<item>
<title>Press Release Jan 27 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-jan-27-2026-12</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-jan-27-2026-12</guid>
<pubDate>Tue, 27 Jan 2026 17:36:18 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".</description>
</item>
<item>
<title>Press Release Jan 12 2026</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-jan-12-2026-9</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-jan-12-2026-9</guid>
<pubDate>Mon, 12 Jan 2026 17:10:35 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 12, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Tentative Approval for BosutinibTablets, 400 mg".</description>
</item>
<item>
<title>Press Release Dec 18 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-dec-18-2025-9</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-dec-18-2025-9</guid>
<pubDate>Thu, 18 Dec 2025 16:02:02 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Travoprost Ophthalmic Solution".</description>
</item>
<item>
<title>Press Release Dec 11 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-dec-11-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-dec-11-2025-3</guid>
<pubDate>Thu, 11 Dec 2025 16:54:29 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%".</description>
</item>
<item>
<title>Press Release Nov 15 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-15-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-15-2025-3</guid>
<pubDate>Sat, 15 Nov 2025 14:10:43 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 15, 2025, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg".</description>
</item>
<item>
<title>Press Release Nov 13 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-13-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-13-2025-11</guid>
<pubDate>Thu, 13 Nov 2025 16:53:39 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg.".</description>
</item>
<item>
<title>Press Release Nov 07 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-07-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-07-2025-18</guid>
<pubDate>Fri, 07 Nov 2025 20:04:31 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Sumatriptan Injection USP, 4 mg/0.5 mL and 6 mg/0.5 mL, Single-Dose Autoinjector System".</description>
</item>
<item>
<title>Press Release (Revised) Nov 04 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-revised-nov-04-2025</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-revised-nov-04-2025</guid>
<pubDate>Tue, 04 Nov 2025 20:25:48 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a revised press release dated November 04, 2025, titled "Revised Press Release for the Q2 FY 26 Results".</description>
</item>
<item>
<title>Press Release Nov 04 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-04-2025-23</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-nov-04-2025-23</guid>
<pubDate>Tue, 04 Nov 2025 19:41:40 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Please find attached herewith the Press Release for the Q2 FY 26 Results".</description>
</item>
<item>
<title>Press Release Oct 29 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-oct-29-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-oct-29-2025-18</guid>
<pubDate>Wed, 29 Oct 2025 15:58:03 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Ticagrelor Tablets, 60 mg".</description>
</item>
<item>
<title>Press Release Oct 18 2025</title>
<link>https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-oct-18-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/alembic-pharmaceuticals-limited/news/press-release-oct-18-2025-7</guid>
<pubDate>Sat, 18 Oct 2025 21:57:00 GMT</pubDate>
<description>Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 18, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL (Single-Dose and Multiple-Dose Vials)".</description>
</item>
</channel>
</rss>